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Abstract: 
Work has continued on the investigation of plants, collected mainly from tropical rainforests, as potential 
sources of new cancer chemotherapeutic agents. About 400 primary samples are obtained each year, with the 
chloroform-soluble extract of each being screened against a battery of in vitro assays housed at the three 
consortial sites in our current National Cooperative Drug Discovery Group (NCDDG) research project. An 
HPLC-MS dereplication procedure designed to screen out “nuisance” compounds has been refined. Several 
hundred secondary metabolites that are active in one or more of the primary assays utilized have been obtained 
in the project to date, and are representative of wide chemical diversity. Some of these are also active in various 
in vivo assays, inclusive of the hollow fiber assay, which was installed recently as part of our collaborative 
research effort. A number of bioactive compounds of interest to the project are described. Keywords: Plants, 
secondary metabolites, anticancer activity, biological testing, activity-guided fractionation, dereplication. 
 
Article: 
Introduction 
Cancer remains a major obstacle to overall public health, and is responsible for one in every four deaths in the 
United States. It was estimated by the American Cancer Society that in 2003 there would be 1,334,100 new 
cases of invasive cancer diagnosed, and 556,500 deaths from this cause. In addition, over one million additional 
people will be diagnosed with basal and squamous cell skin cancers (Jemal et al., 2003). However, as a 
contribution towards the chemotherapy of cancer, natural product secondary metabolites from plants and 
microbes in particular play a very important role in the amelioration of this group of diseases (Shu, 1998; Cragg 
& Newman, 2000; Cragg et al., 2000; Newman et al., 2000). In a recent review dealing, in part, with an analysis 
of the antineoplastic drugs available in western countries and Japan, of 140 compounds in total, a majority 
(54%) are either natural products (14%), natural product derivatives (26%), or compounds made by total 
synthesis, but modeled on natural product leads (14%) (Newman et al., 2003). Accordingly, there is a 
considerable scientific and commercial interest in the continuing discovery of new anticancer agents from all 
natural product sources, inclusive of plant secondary metabolites (Mann, 2002). 
 
As one of several groups funded through the National Cooperative Drug Discovery Group (NCDDG) 
mechanism (Suffness et al., 1995; Cragg et al., 2000), the College of Pharmacy, University of Illinois at 
Chicago, Chicago, IL and the Natural Products Laboratory, Research Triangle Institute, Research Triangle Park, 
NC have collaborated for nearly 15 years. Our current industrial partner in this NCDDG project is Bristol-
Myers Squibb, Pharmaceutical Research Institute, Princeton, NJ (1995–present). During the period 1990–1995, 
Glaxo Wellcome Medicines Research Center, Stevenage, U.K. were involved in our NCDDG program as the 
industrial partner. The major objective of our joint research program is the discovery of new antitumor agents 
from plants. At present, four classes of anticancer agents used clinically in the United States are plant-derived, 
namely, the Vinca alkaloids, the epidodophyllotoxin, the taxanes, and the camptothecin derivatives (Newman et 
al., 2000), with two co-authors of this review having co- discovered camptothecin and paclitaxel (Wall & Wani, 
1996; Wall, 1998). In the present review, the general botanical, biological testing, and phytochemical aspects of 
the program will be discussed in turn, followed by examples of bioactive compounds investigated recently. In 
prior literature contributions, our NCDDG program was reviewed in terms of both the organizational aspects 
and the plant secondary metabolite leads obtained (Cordell et al., 1993; Kinghorn et al., 1995, 1998, 1999). 
 
Plant collections 
The major focus of the plant collection aspects of our NCDDG program has been on plants from the world’s 
tropical rainforests. We have chosen to work on tropical rainforest plants for several reasons. First, the tropical 
forests sustain considerable biodiversity, and, in some of these, more tree species are found in a 0.5 km2 area 
than all of North America (Burslem, 2001). Second, there is justifiable concern about the impending loss of all 
tropical species, so some of these species may not be available to future generations of natural product drug 
discovery scientists (Cox, 2000). Thus, it has been estimated that of the total number of higher plants on earth 
(310,000 to 422,000), about 120,000 of these are tropical endemic species. Moreover, some biodiversity “hot 
spots” with high floristic diversity are undergoing major habitat loss (Myers et al., 2000; Pitman & Jørgensen, 
2002). 
 
In our collaborative work, initial specimens of about 400 plant samples are collected annually, mainly from 
tropical rainforest regions. Over the period 1990–2003, 5886 total plant accessions were obtained, from a total 
of 34 countries. These comprise 2528 species, 1358 genera, 213 families and represent an increasingly valuable 
project resource. In recent years, large proportions of our samples have come from Indonesia and Peru. Priority 
is given to species endemic in the country of collection, and, for many of these, there are no previous 
phytochemical reports available in the literature. Taxonomic authentification is carried out primarily in the 
countries where the collections are made, and are verified by one of us (D.D.S.) at the Field Museum of Natural 
History, Chicago. Plant collections are made only in countries where there is a previously negotiated, formal 
written collection agreement. Much time has been spent in formulating such “benefit sharing” policies over the 
years, in order that institutions in the source countries of the plants concerned receive equitable compensation, 
such as a fair share of any licensing agreement and/or royalty payments (e.g., Soejarto et al., 2002). 
 
It has been the usual practice of our research program to collect up to four anatomical plant parts for each 
species, if readily available. In a recent investigation on the plant, Picramnia latifolia Tul. (Simaroubaceae), 
collected in Peru, both the roots and leaves were studied in detail by activity- guided fractionation, using two 
cancer cell lines to monitor purification. While two known anthraquinones were found in both plant parts, 
anthraquinone glycosides and benzanthrones were present only in the roots, and some new anthrone- and 
oxanthrone C-glycosides occurred exclusively in the leaves of P. latifolia (Díaz et al., 2004b). In a similar 
manner, different profiles of xanthone secondary metabolites were obtained from the leaves, stem bark, and 
twigs of Cratoxylum sumatranum Blume (Clusiaceae) collected in Indonesia, as described in more detail later 
in this review, together with some unusual, but inactive, anthraquinobenzophenones found only in the stem bark 
(Seo et al., 2002). Therefore, the chemical diversity available to the overall investigation can be enhanced if 
more than one plant part is collected (Seo et al., 2002; Díaz et al., 2004b). Even for the same plant part collected 
in the same country, the local conditions at the collection site appear to be important. For example, when 
samples of the bark of Diospyros maritima Blume (Ebenaceae) were collected from two distinct regions and 
habitats in Indonesia, different phytochemical profiles were encountered. One of these samples was collected in 
West Java at sea level, in which naphthoquinone dimers predominated, and the other obtained in Lombok 
Island at ca. 350 meters in altitude, where methoxylated and methylated naphthoquinone monomers were 
prevalent (Gu et al., 2003). 
 
Previously, members of our group have utilized plot-based plant collection as a strategy in natural products 
drug discovery projects (Calderon et al., 2000; Soejarto, 2000). In addition to collecting samples from the 
tropical rainforests in the last few years, we have also performed a pilot project in which plot inventories have 
been established in three locations of hardwood forests in southern Florida, known as “hammocks”. From these 
collections, 71 species from 46 plant families were collected, and the extracts prepared from these species were 
subjected to biological screening. Appropriate local permission was obtained before the initiation of this study 
in 1999, and we agreed not to collect the bark and roots of any species of interest. A number of the species col-
lected are native to Central America and the Caribbean region and were introduced into southern Florida as a 
result of previous hurricane activity (Lobo-Echeverri, 2003). 
 
For promising leads, it is often necessary to obtain a plant recollection (1–5kg), for further biologial and 
chemical investigation. In the project to date, nearly 200 recollections have been made. Care is taken during 
recollections to obtain, as far as possible, the same plant part, at the same time of the year, and from the same 
geographical location as the initial collection. The plot-based approach to plant collection mentioned above 
makes it relatively easy to perform recollections of active plant leads, which are obtained from marked 
specimens within the plot, and serve as a living reference samples (Soejarto, 2000). 
 
In order to guide the selection of future plant collections, a survey using the NAPRALERTSM database has been 
conducted of plants used ethnomedically against cancer. Altogether, 350 species in over 280 genera and 100 
families were listed that were not included in the earlier seminal series of reviews published in the journal 
Lloydia (now the Journal of Natural Products) by Jonathan Hartwell, entitled “Plants used against cancer: a 
survey” (Graham et al., 2000). 
 
Biological testing 
Our project has continued to evaluate the crude chloroform- soluble extracts of plants in a diverse battery of 
cell-based and mechanism-based in vitro assays, which are now performed mainly using 96-well plates. This 
approach has been described in previous reviews of our NCDDG program (Cordell et al., 1993; Kinghorn et al., 
1995, 1997, 1999). A key aspect of the program is the need to select in vitro active leads for activity-guided 
fractionation, and this is accomplished through several strategies, including chemical and biological 
dereplication, which is described in a subsequent section. Active extracts for which there is no obvious chemical 
class of bioactive principle may be subjected to evaluation in an Oncology Diverse Cytotoxicity Assay panel at 
Bristol-Myers Squibb (Cui et al., 1999; Seo et al., 2002). Plant extracts with selective and potent cytotoxicity in 
this panel may then be evaluated directly in the P388 in vivo murine leukemia model (Rose et al., 1988; Peraza-
Sânchez et al., 2000; Seo et al., 2002). P388 in vivo-active extracts that do not contain common plant secondary 
metabolites likely to be responsible for their activity are assigned for activity-guided fractionation with high 
priority. Once isolated in pure form, active compounds are evaluated in all of the in vitro assays available to the 
program. We have recently introduced the in vivo hollow fiber assay at the College of Pharmacy, University of 
Illinois at Chicago, and a summary of how this is used to select compounds for additional biological testing is 
presented in the following paragraphs. 
 
The in vivo hollow fiber assay for the evaluation of potential anticancer agents was developed originally at the 
National Cancer Institute (Casciari et al., 1994; Hollingshead et al., 1995; Hall et al., 2000). Using this method, 
confluent layers of cells from a tumor model of interest are harvested, collected by centrifugation, and 
resuspended in the condi tioned medium at a concentration of 10
6
 or 5 x 10
5
 cells per ml. Polyvinylidine 
fluoride hollow fibers filled with cell suspensions are then incubated in 6-well plates overnight at 37'C in a 5% 
CO2 atmosphere. Female athymic NCI nu/nu mice, obtained from the National Cancer Institute-Frederick 
Cancer Research Facility (Frederick, MD) are then implanted with up to six hollow fibers cultured in one of two 
compartments, either intraperitoneal (i.p.) or subcutaneous (s.c.). For i.p. implants, a small incision is made 
through the skin and musculature of the dorsal abdominal wall of the mouse, with the fibers inserted into the 
peritoneal cavity in a craniocaudal direction, and the incision closed with skin staples. In the case of the s.c. 
implants, a small skin incision is made at the nape of the neck to allow the insertion of an 11 -gauge tumor 
impant trochar containing the hollow fibers. This trochar is inserted caudally through the subcutaneous tissues, 
with the fibers then deposited during the withdrawal of the trochar, and the incision is closed with skin staples 
(Hollingshead et al., 1995; Mi et al., 2002c). The test mice are then randomized into control groups and 
compound treatment groups, with test compounds administered by i.p. injection from days 3–6 after 
implantation. Body weights are determined daily. On day 7, mice are sacrificed, and the fibers are retrieved. 
The fibers are then placed into 6-well plates, with each well containing culture medium and allowed to 
equilibrate for 30 min at 37'C. The viable cell mass contained within each hollow fiber is determined with a 
MTT [3-(4,5-demethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] dye conversion method. After incubating 
suitable aliquots of the culture medium and the MTT solution for 4 hours, the culture medium is removed, and 
2.5% protamine sulfate solution added, with the plates stored at 4°C for 2–4h. To assess the optical density of 
the samples, fibers are transferred to 24- well plates, cut in half, and dried overnight. Formazan is then extracted 
from each sample with DMSO for 4 h on a rotation platform. Aliquots of the extracted formazan are then trans-
ferred to individual wells of 96-well plates and assessed for optical density at 540 nm. The effect of the 
treatment regimen is determined by the net growth percentage of cells relative to changes in body weight 
(Hollingshead et al., 1995; Mi et al., 2002c). 
 
The feasibility of using this in vivo hollow fiber assay as a secondary biological discriminator to select 
promising in vitro-active natural products for additional in vivo biological testing has been examined in some 
detail. Growth conditions have been established for over ten cancer cell lines that can be implanted into the i.p. 
and s.c. compartments of athymic mice. Several model cytotoxic agents were evaluated in this test system, and 
this method can provide a preliminary indication of the potential therapeutic efficacy of natural products 
quickly and at a relatively low expense, with comparatively small amounts of test compound required (e.g., 25 
mg). Compounds which give positive responses at the s.c. site seem to be of more importance for follow-up 
testing than those showing activity only at the i.p. site in the in vivo hollow fiber assay (Mi et al., 2002c). 
 
To exemplify the use of this assay, two compounds will be considered from our NCDDG program. The first of 
these is 13-hydroxy-15-oxozoapatlin, which was obtained initially in our program as a new compound from the 
root bark of the plant, Parinari curatellifolia Benth. (Chrysobalanaceae), collected in Zimbabwe (Lee et al., 
1996). A larger quantity of this broadly cytotoxic compound was provided from a collaborative isolation study 
on Parinari sprucei Hook. f., collected in Venezuela (Braca et al., 2004). Thus, 13- hydroxy-15-oxozoapatlin 
was examined in the hollow fiber model at doses of 25, 50, 75, and 100mg/kg, after it was shown to be 
cytotoxic toward cultured KB (nasopharyngeal), LNCaP (human hormone-dependent prostate), and Lu1 
(human lung) cells, with ED50 values of 1.2, 1.5, and 5.1 mg/ml, respectively. It showed more than 50% growth 
inhibition with KB and LNCaP cells (up to 68.7 and 87.7% respectively at the i.p. site, but no significant growth 
inhibition was observed with Lu1 cells (Fig. 1, panel A). There was no evidence of activity at the s.c. site for 
any of the cell types studied. In addition, this compound produced no indication of body weight loss in the 
hollow fiber assay, suggesting that it would be worthy of additional biological testing in an in vivo model 
(Braca et al., 2003). Mechanistically, 13-hydroxy15-oxozoapatlin was found to be a G2 DNA damage check-
point inhibitor and to exhibit antimitotic activity (Rundle et al., 2001). 
 
The second compound chosen as an example after evaluation in the hollow fiber assay is plumbagin, which was 
isolated in our investigation of the bark of Diospyros maritima, collected in Indonesia (mentioned above). 
Plumbagin was the most potent cytotoxic naphthoquinone found in our study (Gu et al., 2003), and is well-
known as a bioactive principle of many medicinal plants (Shen et al., 2003). This compound was shown to be 
cytotoxic towards cultured KB, LNCaP, and Lu1 cells with ED50 values of 0.1, 0.8, and 0.3 mg/ml, 
respectively. Accordingly, plumbagin was evaluated in the hollow fiber assay against these same three cell 
types at doses of 1.25, 2.5, 5.0, 7.5, and 10 mg/kg. However, the two highest doses were lethal to one or more 
mice, and a dose of 5 mg/kg caused significant weight loss. Since no significant growth inhibition was observed 
at either the i.p. or the s.c. sites with KB, LNCaP, and Lu1 cells for all of the non-toxic doses (Fig. 1, panel B), 
this compound is not regarded as a very promising lead for further development as a cancer chemotherapeutic 
agent (Gu et al., 2003). 
 
Providing compound quantities permit, and the compounds elicit sufficient interest from the project senior in-
vestigators after evaluation in the Bristol-Myers Squibb Oncology Diverse Cell Assay and/or the hollow fiber 
assay at UIC, pure plant-derived compounds found to be active are then evaluated in the P388 in vivo assay at 
B-MS, using both the i.p. and s.c. routes of administration (Rose et al., 1988; Peraza-Sánchez et al., 2000; Seo 
et al., 2002). Other in vivo test systems that may be used are the M109 murine lung carcinoma and the HCT116 
human colon carcinoma models (Cui et al., 1999). 
 
For active compounds of particular interest to the program, we conduct preliminary mechanistic studies on cell-
cycle arrest and apoptosis induction (e.g., Cui et al., 1999). In addition, compounds may be submitted to the 
National Cancer Institute for mechanism of action evaluation in the 60 cell-line panel via COMPARE analysis 
(Lee et al., 1994). More detailed mechanism of action work of active compounds isolated in our NCDDG 
project has also been carried out at the University of Illinois at Chicago. For example, the common plant 
triterpenoid, betulinic acid, was isolated several years ago in our work on Ziziphus mauritiana Lam. 
(Rhamnaceae), and found to exhibit melanoma-specific cytotoxicity caused by the induction of apoptosis, and 
to exhibit an antitumor effect for human melanoma xenografts carried by athymic mice (Pisha et al., 1995). 
Recently, continued mechanistic studies have shown that treatment of UISO-Mel-1 human melanoma cells with 
betulinic acid leads to the activation of p38 and stress-activated protein kinase/cJun NH2-terminal kinase (Tan 
et al., 2003). 
 
Phytochemical procedures 
For several years, we have used a simple solvent extraction scheme for all new primary plant collections. Thus, 
a small quantity (20 g) of each dried and powdered plant is extracted into methanol-water (9: 1), then defatted 
with hexanes. The resultant aqueous methanol partition is then extracted with chloroform. Each chloroform 
extract is then washed with 1% sodium chloride, which enables it to be relatively free from plant polyphenols, 
which are known to interfere with certain in vitro bioassays (Wall et al., 1996). Bioactive compounds are 
isolated by activity-guided chromatographic fractionation using standard techniques, and their structures are 
determined by spectral data interpretation. When the need arises, the compound structures are confirmed using 
single-crystal X-ray crystallography (e.g., Ito et al., 2000; Chávez et al., 2001). To facilitate the determination 
of absolute stereochemistry of natural product isolates containing a secondary hydroxyl group, a convenient 
technique has been developed recently at the University of Illinois at Chicago. This involves preparing Mosher 
esters directly in NMR tubes, which are then directly measured, thus obviating the need to purify these 
derivatives chromatographically (Su et al., 2002). 
 
To avoid reisolating known bioactive compounds as far as possible, we have used a LC-MS dereplication 
procedure in our NCDDG program for several years (Constant & Beecher, 1995; Cordell et al., 1997; Cordell 
& Shin, 1999; Kinghorn et al., 1999). Previously, we developed an integrated on-line LC-MS-bioassay protocol 
combined with database searching, which enabled the molecular ions of cytotoxic compounds to be detected. In 
this manner, it is possible to rank extracts for subsequent activity-guided fractionation, with a higher priority 
accorded to extracts for which the active region of a chromatogram is not associated with any known cytotoxic 
compound. On the other hand, when there is a high 
 
probability that a known active compound is responsible for the cytotoxicity observed, extracts of this type are 
given a lower priority for phytochemical fractionation (Cordell et al., 1997; Kinghorn et al., 1999). 
 
A new off-line dereplication system has been developed in the last two years, and is comprised of separate 
fractionation, bioassay, and mass spectral analytical steps. In brief, extracts that have shown bioactivity in 
preliminary screening are chromatographed by reversed-phase HPLC using a standard 30-minute gradient, and 
fractions distributed onto 96- well plates. One or more of these plates is submitted for biological testing in the 
same assay in which activity is shown initially, and a duplicate plate serves as a fraction library for the LC-ms 
analysis of the wells corresponding to the active fractions. An Agilent Series HPLC-MSD instrument, with an 
auto-sampler, an electrospray ionization (ESI) source, a single quadrupole analyzer, and a photodiode array 
detector is used. Database searching primarily with the NAPRALERT
SM
 and SciFinder
®
 Scholar databases, for 
reported cytotoxic compounds, using taxonomic restrictions (usually in the same family, genus, and/or species), 
yields a list of possible matches. Masses measured for the active fractions are compared with the masses of 
reported cytotoxic compounds. If the active compounds match one another, the extract under consideration is 
given a low priority for subsequent activity-guided fractionation. This new method allows greater convenience 
and flexibility than previously, including the capability to perform accurate mass and MS/MS determinations 
(Jones et al., 2003). 
 
As part of a method-validation study, this procedure was used to evaluate separate extracts of the leaves and 
twigs of an undetermined Elaeocarpus species collected in Indonesia. As a result, the known cytotoxic agents 
cucurbitacins D and F were determined as being present in both extracts, so this species was not selected for 
phytochemical study. It was also deemed unnecessary to identify this plant acquisition to the species level 
(Jones et al., 2003). We have previously examined in some detail the cucurbitacin and ellagic acid constituents 
of Elaeocarpus mastersii King (Elaeocarpaceae) (Ito et al., 2002). 
 
Examples of bioactive compounds recently isolated and evaluated 
The structures of a number of active compounds isolated and characterized in our recent work in our NCDDG 
project are shown in Figure 2. The examples shown have been chosen to complement those included in our 
most recent review on this project (Kinghorn et al., 1999). 
 
Alkaloids-tropane 
As a result of the bioactivity-guided fractionation of a chloroform-soluble extract of the roots of Erythroxylum 
pervillei Baillon (Erythroxylaceae), collected in southern Madagascar, nine tropane alkaloid esters were isolated 
and characterized; seven of these were found to be new alkaloids. Six of the new compounds (pervilleines A–F, 
1–6) were found to reverse multidrug resistance (MDR), using a KB-V1 (vinblastine-resistant oral epidermoid 
carcinoma) cell line in the presence of vinblastine. The parent alkaloid, pervilleine A (1), was assigned 
structurally as 3a-(3,4,5-trimethoxybenzoyloxy)-60-(E)-(3,4, 5-trimethoxycinnamoyloxy)-70- 
hydroxytropane. Like pervilleine A (1), pervilleines B-F (2–6) also bear a trimethoxycinnamate ester group at 
position C-6, but exhibit minor structural variations in the nature of the aromatic ester unit affixed to C-3, and 
may or may not be hydroxylated at C-7. All of these six compounds were much less cytotoxic for normal KB 
cells and the other cancer cell lines in the UIC tumor panel than for KB-V1 cells in the presence of vinblastine; 
although some were more broadly cytotoxic than others. Confirmatory results were obtained for several of the 
pervilleines with MDR-resistant SKVLB human ovarian adenocarcinoma cells in the presence of adriamycin, 
and in a synergistic study performed with several cell lines from the NCI tumor panel (Silva et al., 2001). The 
N-oxide derivative of pervilleine A was also isolated in this investigation, but was shown to be devoid of 
inhibitory effects for either the KB-V1 or any of the other cell lines in the tumor panel (Silva et al., 2001). 
 
Pervilleine A (1) was examined in more depth mechanistically, and was found to restore the vinblastine 
sensitivity of cultured KB-V1 and CEM/VLB100 (multidrug-resistant human leukemic lymphoblast CEM) cells 
with IC50 values of 0.36 and 0.02µM, respectively. In a similar manner, the chemosensitivity to colchicine of 
the KB-8-5 drug-resistant cell line, was restored by pervilleine A, with an IC50 value of 0.61 µM. Pervilleine A 
(1) inhibited competitively the binding of [
3
H]vinblastine with isolated KB-V1 cell membrane vesicles. The 
effect of pervilleine A was then studied in the hollow fiber test, as described briefly as follows. It was 
established earlier in preliminary growth assays that a suitable concentration of hollow fibers for KB-3 (non-
drug resistant) cells and KB-V1 cells was 7.5 x 10
5
 cells per ml. Also, it was determined that a dose of 150 
µg/kg of vinblastine inhibited the growth of KB-3 cells without influencing KB-V1 cells, and that neither KB-3 
nor KB-V1 cells were sensitive to the effects of pervilleine A at a dose of 0.136 mmol/kg. However, when 
vinblastine was co-administered with pervilleine A at these concentrations, a ca. 75% growth inhibitory effect 
was observed with KB-V1 cells implanted at the i.p. site. Equimolar doses under the same conditions of 
verapamil, a standard MDR inhibitor, were less effective than pervilleine A. This study was the first use of the 
hollow fiber assay to evaluate MDR-reversing agents in combination with a cancer chemotherapeutic agent, and 
it was concluded that pervilleine A is an effective inhibitor of P-glycoprotein (Mi et al., 2001). The in vitro P-
glycoprotein activities of pervilleines B (2), C (3), and F (6) were confirmed in the in vivo hollow fiber assay, 
when co-administered with vinblastine, in the same manner as described for pervilleine A (1) (Mi et al., 2002b, 
2003). All four compounds showed similar levels of reversing activity in this assay, but it was noted that 
pervilleine F (6) did not cause any test animal body weight loss, in contrast to 1–3, where slight body weight 
losses were observed (Mi et al., 2001, 2002b, 2003). 
 
The stems of a second species in the genus Erythroxylum were collected in the Dominican Republic, and four 
additional tropane alkaloid aromatic esters were isolated from E. rotundifolium Lunan with the ability to reverse 
the multidrug-resistance phenotype (compounds 7–10). Of these, alkaloids 8–10 were already known, and the 
new alkaloid 7 had an unusual Z-3,4,5-trimethoxycinnamyl ester unit affixed to C-3. Moreover, a second new 
alkaloid, 11, was isolated from E. robustifolium, which is identical in structure to 
 
pervilleine A (1) in all respects except that the C-3 and C-6 aromatic ester substituents are interchanged. 
However, compound 11 proved to be broadly, but weakly, cytotoxic for the UIC tumor panel, with its 
specificity lost for the drug- resistant KB-V1 cell line (in the presence of vinblastine) (Chávez et al., 2002). 
 
The pervilleines (A–C and F, 1–3 and 6) are prominent among the compounds discussed in this review, since 
they are novel inhibitors of the MDR phenotype. In our recent work, it has been shown that these four aromatic 
tropane alkaloids mediate potent activity with several in vitro and in vivo models, and that they meet the general 
structural 
 
requirements of other MDR modulators in possessing planar aromatic rings and a nitrogen atom (Zamora et al., 
1988; Mi et al., 2002a). Analysis of all of the MDR-inhibitory and inactive tropane alkaloid esters obtained 
from both E. pervillei and E. robustifolium has permitted a preliminary notion of the structural requirements 
needed for selective cytotoxicity for the KB-V1 cell line in the presence of vinblastine. Thus, optimal activity is 
shown when there is an E-3,4,5-trimethoxycinnamyloxy (Tmc) exo substituent at C-6. A benzoate (Bz) ester is 
also permissible at this same position, but not a 3,4,5-trimethoxybenzoyl (Tmb) unit (Mi et al., 2002a). There 
was very little difference in the cytotoxicity profiles of compounds 7 and 8, so the trans- or cis- stereochemistry 
in the Tmc ester unit appears to be of little biological consequence in this regard. There seems to be con-
siderable structural latitude in the types of groups that can be substituted at C-3 ((x configuration) if a C-6 Tmc 
exo unit is present. MDR reversal persists with any of a Tmc, a Tmb, a phenylacetyl, or a 3-
hydroxyphenylacetyl unit. An exo OH group at C-7 is also permitted, as in pervilleine A (1), but may be absent, 
as in pervilleines B (2), C (3), and F (6). On further probing their in vitro MDR modulating effects, pervilleines 
A–D (1–4) and F (6) were found to enhance the intracellular accumulation of a fluorescent dye, rhodamine 123, 
in drug-resistant MDR KB-V1 cells, as confirmed by visualization using confocal microscopy (Mi et al., 
2002a). However, it was found that when ClogP and molecular refractivity data were determined for selected 
tropane alkaloids from E. pervillei and E. robustifolium, these values correlated only weakly with the propensity 
of these alkaloids to reverse MDR (Mi et al., 2002a). 
 
In a more recent in vitro study performed on pervilleine F (6), this alkaloid was shown, at a non-toxic dose of 8 
µM, to partially reverse the cross-resistance of clinically used or experimental anticancer agents, as follows: 
actinomycin (45.1-fold), baccatin III (>3.4-fold), daunomycin (>22.5-  fold), ellipticine (1.9-fold), mithramycin 
A (42.5-fold),  podophyllotoxin (1.6-fold), paclitaxel (32.2-fold), and vincristine (73.6-fold). No effect was 
observed with etoposide. The comparable figures for verapamil, when tested at the same dose, were: 
actinomycin D (82.2-fold), baccatin III (>5.9-fold), daunomycin (>32.8-fold), podophyllotoxin (2.1- 
fold), paclitaxel (20.8-fold), and vincristine (88.3-fold). In this case, no effects were found with ellipticine, 
etoposide, and mithramycin A. These evaluations were performed by determining the IC50 ratios of drug-
resistant KB-3 cells and normal KB-3 cells. While generally potent in reversing cross- resistance to many 
anticancer agents, it may be pointed out that ellipticine, etoposide, and podophyllotoxin interact with 
topoisomerase II, an atypical multidrug resistance, rather than P-glycoprotein (Mi et al., 2003). 
 
Alkaloids – phenanthoindolizidine 
Bioassay-directed study of the leaves and twigs of Ficus hispida L. f. (Moraceae), collected in Thailand, led to 
the isolation of a potent cytotoxic agent, O-methyltylophorinidine (12), a phenanthroindolizidine alkaloid of 
previously known structure (Govindachari et al., 1974). This alkaloid was highly cytotoxic, exhibiting ED50 
values in the Col2 (human colon), KB, Lu1 (human lung), and LNCaP (human hormone-dependent prostate) 
cancer lines of 0.02, 0.02, 0.018, and 0.03 µg/ml, respectively. Unfortunately, compound 12 was isolated in too 
small an amount for follow-up biological testing (Peraza-Sânchez et al., 2002). Recently, Staerk and associates 
have also pointed to the high cytotoxic potency for cancer cell lines of several phenanthroindolizidine alkaloids 
in the low nanomolar range, and have suggested that the known neurotoxicity and other side effects of these 
alkaloids could be overcome by modern tissue- specific, drug targeting techniques (Staerk et al., 2002). 
 
Diterpenoids – norkaurane 
Exostema acuminata Urb. (Rubiaceae) is native to Central America and northern South America, and a sample 
of the roots was collected in the Dominican Republic. Activity-guided fractionation using the KB cell line led to 
the isolation of a new norditerpenoid, (16S)-ent-16,17- dihydroxy-19-nor-kaur-4-en-3-one (13), found to be 
weakly cytotoxic, with the best activity being against the LNCaP (hormone-dependent human prostate cancer) 
cell line (ED50 4.8 µg/ml). The structure of this compound was assigned as the 16S epimer of another new 
norditerpenoid, whose structure was determined by single-crystal X-ray crystallography [16R)-ent-16,17-
dihydroxy-19-nor-kaur4-en-3-one (13)], which was not cytotoxic. In addition to these two compounds, six 
broadly cytotoxic phenylisocoumarins of previously known structure were isolated from E. acuminata roots. 
The two most abundant of these, 8-hydroxy-5,7,4'-trimethoxy-4-phenylcoumarin (14) and 5,7,4'-trimethoxy-4-
phenylcoumarin (15), were evaluated in an in vivo P388 murine leukemia model (i.p.) at Bristol-Myers Squibb, 
but neither compound was deemed active, when evaluated at 135 and 24mgkg~
1
 per injection, respectively (Ito 
et al., 2000).  
 
Diterpenoids – clerodane 
Fractionation of the roots of Licania intrapetiolaris Spruce ex Hook. (Chrysobalanaceae) and of the leaves and 
stems of Casearia sylvestris Sw. (Flacoutiaceae), both collected in Ecuador, led to the isolation and 
characterization of five new clerodane-type diterpenoids, intrapetacins A (16) and B (17), and casearvestrins A-
C (18–20). Although fundamentally very similar molecules, these diterpenoids differ in their type of C-20-
substituted ester group and the C-9-affixed side-chain (Oberlies et al., 2001, 2002). Intrapetacins A and B were 
only moderately cytotoxic to the KB cell line, and were accompanied by the widely distributed plant cytotoxic 
agent, cucurbitacin B, in their plant of origin (Oberlies et al., 2001). The three clerodane diterpenoids from C. 
sylvestris were also shown to be active in the KB test system at RTI, and were then evaluated against the LX-1 
(human lung), HCT116 (human colon), and A2780 (human ovarian) cell lines at B-MS, in which they exhibited 
comparable IC50 values for each cell line between 0.20 and 0.82µM. These compounds were not tested further 
because of the limited quantities available (Oberlies et al., 2002). When compared structurally against caesarins 
A-R isolated from other Casearia species earlier, compounds 18–20 would be representative of a group of 
compounds in a second tier of cytotoxic potency, and thus expected to be more potent cytotoxic agents if their 
C-6 P-hydroxy group were absent in each case (Itokawa and Takeya, 1993; Oberlies et al., 2002). Recently,  
other groups have also isolated and characterized cytotoxic clerodane diterpenoids from additional Casearia 
species (Beutler et al., 2000; Prakash et al., 2002). 
 
Naphthoquinones 
Along with three dihydronaphthalenone derivatives with new structures, which were not found to be 
biologically active in our work, four cytotoxic naphthoquinones of known structure (21–24) were isolated from 
the roots of another plant collected in the Dominican Republic, Ekmanianthe longiflora (Griseb.) Urb. 
(Bignoniaceae). One of these bioactive compounds, 2-(1 -hydroxyethyl)naphtho[2,3-b]furan-4,9- quinone (21) 
was found to be broadly cytotoxic in the UIC cancer cell panel (ED50 range 0.2–3.5 gg/ml). It was then 
evaluated in the 25-cell line Oncology Diverse Cell Assay at Bristol-Myers Squibb, representing a diverse 
group of murine and human tumors, fibroblasts, and normal bovine endothelial cells, and found to be active, 
with a mean IC50 value of 2.9gM. However, when subsequently evaluated in the P-388 in vivo system, injected 
i.p. at 72mgkg~
1
, the com- pound was inactive (T/C !!9125%) (Peraza-Sânchez et al., 2000). This compound 
was found to be a cytotoxic agent for KB cells by Rao and Kingston, but it was not tested in vivo at that time 
(Rao & Kingston, 1982). 
 
Polyacetylenes 
The twigs of the southeast Asian tree, Ochanostachys amentacea Mast. (Olacaceae) were investigated, after a 
chloroform-soluble extract was found to exhibit significant cytotoxic activity when evaluated against the UIC 
tumor cell culture panel. Bioassay-guided fractionation using the LNCaP (human hormone-dependent prostate 
cancer) cell line, led to the isolation of three cytotoxic principles, namely, the known polyacetylene, 
minquartynoic acid (25), and two new analogs, (S)-17,18-dihydroxy-9,11,13,15- octadecatetraynoic acid (18-
hydroxyminquartynoic acid, 26) and (S)-17-hydroxy-15E-octadecen-9,11,13-triynoic acid (E-15,16-
dihydrominqurtynoic acid, 27). In our work, the previously unresolved absolute stereochemistry of 25 was 
determined at C-17 as S, using the Mosher ester method (Ito et al., 2001). At the same time as our work was in 
progress, Rasmussen et al. (2000) independently determined the C-17 stereochemistry of 25 by its chemical 
conversion to the known (S)-17-hydroxystearic acid methyl ester. Compound 25 showed broad but weak 
cytotoxic activity in the UIC tumor cell panel, with compound 26 exhibiting a general decrease in cytotoxic 
potency relative to 25. Of the three compounds, 27 was the most potently cytotoxic for the KB (oral epidermoid 
carcinoma), LNCaP, and SW626 (human ovarian) cell lines (ED50 range 0.30–1.1 gg/ml). The supplies of 
compounds 25–27 were too small for the additional biological testing of these polyacetylenes from O. 
amentacea collected in Indonesia (Ito et al., 2001). 
 
Phenols 
Machaerium aristulatum (Spruce ex Benth.) Ducke is a member of the legume family, which grows widely as a 
vine in the Amazon basin. This plant was collected in Peru, and activity-guided fractionation led to the isolation 
and purification of a new cinnamylphenol (macharistol, 28) and a known pterocarpan (+)-medicarpin (29) as 
cytotoxic principles in the KB cell line. When compound 28 was evaluated in the in vivo hollow fiber assay at 
UIC, it was deemed to be inactive at the highest dose tested (25 mg/kg body weight), using the KB, Col-2 
(human colon), and hTERT-RPE1 (human telomerase reverse-transcriptase-retinal pigment epithelial) cells 
(Seo et al., 2001). 
 
Flavones 
Vitex negundo L. (Verbenaceae) is a small aromatic plant with extensive use as a folk medicine in south and 
southeast Asia, particularly as an anti-inflammatory agent (Panthong et al., 1986). The known flavone, 
vitexicarpin (casticin; 5,3'- dihydroxy-3,6,7,4'-tetramethoxyflavone, 30) was found to be the only potent 
cytotoxic agent in a chloroform-soluble extract of V. negundo leaves collected in Indonesia. When evaluated in 
an 11-cell line Oncology Diverse Cell Assay at Bristol-Myers Squibb, this compound was found to exhibit good 
potency and a high selectivity against the K562 human leukemia cell line. Accordingly, several semisynthetic 
derivatives of compound 30 were made, and the new compound 31 exhibited similar cytotoxic profiles to the 
parent compound at both UIC and B-MS. However, compound 31 was inactive in both the hollow fiber assay at 
UIC (evaluated with KB, LNCaP, and Lu1 cells) and the P388 in vivo assay at B- MS (135mg/kg/injection, 
injected i.p.) (Díaz et al., 2003). The mechanism of action of compounds 30 and 31 was not studied in our 
program. However, Ko et al. (2000) have shown that vitexicarpin (30) induces apoptosis in human myeloid 
leukemia cells. Beutler and colleagues (1998) have shown that for polymethoxylated flavones, the maximal 
binding to tubulin occurs in compounds having hydroxyl groups at C-5 and C-3' and methoxyl groups at C-3 
and C4', so it is likely that vitexicarpin (30) inhibits tubulin polymerization, as already noted by Ono et al. 
(2002).  
 
Stilbenes 
A methanol-soluble extract of the root bark of Ekebergia benguelensis C. DC. (Meliaceae), collected in 
Zimbabwe, led to the isolation of three new stilbenoids (32–34). The first of these, 5-[(1E)-2-(4-
hydroxyphenyl)ethenyl]-4,7- dimethoxy-3-methyl-2H-1-benzopyran-2-one (32), was characterized as an 
interesting stilbene-coumarin hybrid molecule based on a novel carbon skeleton, and the structure was proposed 
by single-crystal X-ray crystallography. In turn, compounds 33 and 34 are derivatives of trans-resveratrol 
having an unusual isobutyryl substituent, with compound 33 being considered the biogenetic precursor of 
compound 32. Compounds 32–34 were only weakly cytotoxic for one or two cell lines each, when evaluated in 
the tumor panel at UIC (Chávez et al., 2001). 
 
Xanthones 
During the course of our investigation of various Indonesian plants, six new xanthones, called 
cratoxyarborenones A-F (35–40), were isolated from various plant parts of Cratoxylum sumatranum Blume 
(Guttiferae), which were individually examined. Four of these xanthones, which bear one or more geranyl 
and/or prenyl units (35, 36, 38, and 39) were isolated and characterized from the leaves, while compound 37 
was found in the stem bark, and compound 40 in the twigs (Seo et al., 2002). 
 
These compounds were evaluated against the KB cell line, and all of them were found to exhibit EC50 values in 
the range 1.0–4.3 mg/ml. Due to the availability of a sufficient amount of one of these compounds, 
cratoxyarborenone C (37) was evaluated in the 25 cell-line Oncology Diverse Cell Assay and then in the in vivo 
P388 murine leukemia system at B- MS. However, when tested at 72mg/kg/injection (i.p.), this compound was 
deemed inactive (Seo et al., 2002). Also isolated as a cytotoxic principle (EC50 1.3 mg/ml) in this investigation 
on C. sumatranum was the previously known anthracene derivative, vismione B (41). Vismione A, an 
acetylated derivative of compound 41, was found by earlier investigators to exhibit in vivo activity against an 
ovarian carcinoma and the B16 melanoma models, but not the P388 system (Cassinelli et al., 1986). Two other 
compounds from C. sumatranum, representing a new structural class of geranylated anthraquinobenzophenones 
were also isolated and characterized, but these were not found to be cytotoxic for KB cells in our investigation 
(Seo et al., 2002). 
 
Summary and conclusions 
Although some have questioned the need to prospect the full diversity of nature in order to find leads for new 
drugs (Tulp & Bohlin, 2002), others have challenged this (Cragg & Newman, 2002). In the previous work in 
our multidisciplinary NCDDG project, we have attempted to maximize the plant diversity sampled, through 
collections in both tropical and temperate countries (Cordell et al., 1993; Kinghorn et al., 1995, 1998, 1999). It 
is our intention to develop plant collection agreements with as many new countries as reasonable, and new 
agreements have recently been signed with the Congo and Papua New Guinea. The plot collection approach 
described earlier in this review is worthy of additional investigation, and is particularly advantageous when it is 
necessary to organize plant recollections. 
 
It has been apparent for some time that natural products can serve as excellent biological probes for cellular 
targets that are associated with cancer chemotherapy (Newman et al., 2002). It is to be noted that even 
previously well-known classes of plant-derived secondary metabolites with antineoplastic and/or cytotoxic 
activity, such as cucurbitacins (Blaskovich et al., 2003), ent-kaurene diterpenoids (Lee et al., 2002), 
naphthopyrones (Li et al., 2003), rocaglamide derivatives (Baumann et al., 2001), and simple bisindole 
alkaloids (Marko et al., 2001), have been demonstrated to act on specific cancer-related targets. Accordingly, 
there is value in the isolation and biological and mechanistic evaluation of known compounds along with the 
discovery of new potential antineoplastic agents from plants, since potent and specific biological probes may be 
elucidated. 
 
Previously, betulinic acid was selected for preclinical development through the RAID (Rapid Access to 
Intervention Development) initiative of the National Cancer Institute (Cragg & Newman, 2000; Cragg et al., 
2000). Pervilleines A–C (1–3) and F (6) are also being evaluated in the NCI RAID program, for which the work 
performed so far has involved the recollection of 50 kg each of the roots and stem bark of Erythroxylum 
pervillei from the original collection site in southern Madagascar. These materials have been sent to the 
National Cancer Institute at Frederick, Maryland, where these four pervilleines are being isolated in gram quan-
tities each, and tested in a HT-15 colon carcinoma in vivo hollow fiber assay. In this manner, it is planned to 
select one of the pervilleines currently being investigated (i.e., either pervilleine A, B, C, or F) for further 
preclinical development. 
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